医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Wolters Kluwer Supports Australian, Middle Eastern and Asia Pacific Healthcare Organizations with Introduction of Medi-Span ICD-10-AM Mapping

2015年03月25日 PM09:53
このエントリーをはてなブックマークに追加


 

HUDSON, Ohio

Wolters Kluwer, a leading global provider of information for healthcare professionals and students, announced today that its Clinical Drug Information unit is strengthening support for customers in the Asia Pacific region with the release of the new ICD-10-AM v6 – Disease Mapping™ API. This essential tool will help facilitate the interoperability required by Australian and other regional customers employing drug data from the Clinical Drug Information application Medi-Span®.

ICD-10 is the tenth revision of the International Statistical Classification of Diseases and Related Health Problems, a medical classification list of codes that identify various diagnoses, symptoms, procedures, and other factors involved in reporting and documenting medical care. The codes, maintained by the World Health Organization, help create a standard international data vocabulary for sharing information and communicating diagnoses and other medical information. ICD-10-AM is the “Australian Modification” code set, which has been customized and extended to include new codes and conditions relevant in Australia and the surrounding region.

With the ICD-10-AM v6 – Disease Mapping API, Medi-Span customers in nations such as Australia, Singapore and Saudi Arabia will receive the region-specific data they need to better deliver medication decision support. This new offering is an application programming interface (API) that maps Medi-Span proprietary medical condition codes to the corresponding ICD-10-AM identifiers. This will help improve interoperability and enhance data-driven clinical screenings, including for drug-disease contraindications and condition-specific drug dosing.

“Healthcare professionals in Australia, New Zealand, Singapore, the Middle East and throughout Asia Pacific need relevant data to power their processes. They should not be expected to compromise and adapt to codes designed for the United States, Canada, or Europe,” stated Steven Kerscher, Vice President & General Manager, Clinical Drug Information, Wolters Kluwer Health, Clinical Solutions. “The Clinical Drug Information unit has strong relationships with health systems in the region, and we are proud to provide the data and data mapping those organizations need to optimize their clinical systems and deliver the best possible healthcare.”

About Wolters Kluwer

Wolters Kluwer is a global leader in professional information services. Professionals in the areas of legal, business, tax, accounting, finance, audit, risk, compliance and healthcare rely on Wolters Kluwer’s market leading information-enabled tools and software solutions to manage their business efficiently, deliver results to their clients, and succeed in an ever more dynamic world.

Wolters Kluwer reported 2014 annual revenues of €3.7 billion. The group serves customers in over 170 countries, and employs over 19,000 people worldwide. The company is headquartered in Alphen aan den Rijn, the Netherlands. Wolters Kluwer shares are listed on NYSE Euronext Amsterdam (WKL) and are included in the AEX and Euronext 100 indices. Wolters Kluwer has a sponsored Level 1 American Depositary Receipt program. The ADRs are traded on the over-the-counter market in the U.S. (WTKWY).

For more information about our products and organization, visit www.wolterskluwer.com, follow @WKHealth or @Wolters_Kluwer on Twitter, like us on Facebook, follow us on LinkedIn, or follow WoltersKluwerComms on YouTube.

CONTACT

Wolters Kluwer Health | Clinical Solutions
Meagan McCord,
330-650-6506
Manager, Marketing Communications
meagan.mccord@wolterskluwer.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • ADCセラピューティクスが当社の新規抗体薬物複合体ADCT-402の第I相中間データを発表
  • Vedanta Biosciences Granted Four New U.S. Patents Expanding Coverage for Compositions and Methods of Use for Therapeutics Based on Microbiome-Derived Bacterial Consortia
  • Daiichi Sankyo and Puma Biotechnology Announce Research Collaboration with Major Cancer Center in HER2-Mutated Cancer
  • 武田和Seattle Genetics呈报3期ECHELON-1临床试验的阳性数据,该试验评估ADCETRIS® (brentuximab vedotin)用于晚期霍奇金淋巴瘤的一线治疗
  • ADCセラピューティクスが当社の新規抗体薬物複合体ADCT-301の第I相中間データを発表